Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients

Therapeutic Drug Monitoring

Volumn 27, Issue 4, 2005, Pages 422-430

  Zahir, Hamim ^a   McLachlan, Andrew J ^b   Nelson, Ameeta ^b   McCaughan, Geof ^c   Gleeson, Margaret ^c   Akhlaghi, Fatemeh ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Albumin; Hematocrit; Liver transplant; Population pharmacokinetics; Tacrolimus

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; DILTIAZEM; FLUCONAZOLE; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; ORAL ANTIDIABETIC AGENT; PANTOPRAZOLE; PHENYTOIN; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ADULT; AGE; ANALYTIC METHOD; ANEMIA; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG APPARENT CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; GENDER; HEMATOCRIT; HUMAN; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONLINEAR MIXED EFFECT MODELING; PHARMACOKINETICS; POPULATION; POPULATION PHARMACOKINETICS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ALGORITHMS; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FLUCONAZOLE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDNISOLONE; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 23244459511     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000170029.36573.a0     Document Type: Article

References (29)

1. Ihara H, Shinkuma D, Ichikawa Y, et al. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients-importance of trough level as a practical indicator. Int J Ur0l. 1995;2:151-155.
2. Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995;57:281-290.
3. Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002;72:660-669.
4. Lee C, Jusko WJ, Shaefer MS, et al. Pharmacokinetic of tacrolimus (FK506) in liver transplant recipients. Clin Pharmacol Ther. 1993;53:181.
5. Sam WJ, Aw M, Quak SH, et al. Population pharmacokinetics of tacrolimus in Asian pediatric liver transplant patients. Br J Clin Pharmacol. 2000;50:531-541.
6. Staatz CE, Taylor PJ, Lynch SV, et al. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation. 2001;72:1056-1061.
7. Zahir H, McCaughan G, Gleeson M, et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004;57:298-309.
8. Christiaans M, van Duijnhoven E, Beysens T, et al. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc. 1998;30:1271-1273.
9. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430.
10. Nagase K, Iwasaki K, Nozaki K, et al. Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol. 1994;46:113-117.
11. Zahir H, Nand RA, Brown KF, et al. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods. 2001;46:27-35.
12. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753-761.
13. Stiff DD, Venkataramanan R, Prasad TN. Metabolism of FK 506 in differentially induced rat liver microsomes. Res Commun Chem Pathol Pharmacol. 1992;78:121-124.
14. Ericzon BG, Ekqvist B, Groth CG, et al. Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. Transplant Proc. 1991;23:2775-2776.
15. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc. 1990;22:57-59.
16. Staatz CE, Lynch SV, Balderson G, et al. The population pharmacokinetics of tacrolimus in 30 adult liver transplant recipients. ASCEPT Proc. 1998;5:89.
17. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
18. Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation. 1994;57:519-525.
19. Jain AB, Fung JJ, Tzakis AG, et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. Transplant Proc. 1991;23:2763-2766.
20. Venkataramanan R, Shaw LM, Sarkozi L, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41:542-551.
21. Karlsson MO, Jonsson EN, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26:207-246.
22. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-252.
23. Booth BP, Gobburu JV. Considerations in analyzing single-trough concentrations using mixed-effects modeling. J Clin Pharmacol. 2003;43:1307-1315.
24. Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57:479-484.
25. Brunei M, Torregrosa JV, Oppenheimer F, et al. Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow-up. Transplant Proc. 1998;30:4068-4069.
26. Molinaro M, Regazzi MB, Pasquino S, et al. Pharmacokinetics of tacrolimus during the early phase after heart transplantation. Transplant Proc. 2001;33:2386-2389.
27. Pou L, Brunei M, Bilbao I, et al. Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK506 multicenter Spanish Study Group: a two-year follow-up. Ther Drug Monit. 1998;20:602-606.
28. Osowski CL, Dix SP, Lin LS, et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation. 1996;61:1268-1272.
29. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother. 1999;33:680-682.